We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
News

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
News

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, today announced it has signed a collaboration with Cancer Research UK for the further development of immatics’ therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 to be carried out at leading glioma research centres in the UK via its Drug Development Office. immatics will supply the drug IMA950 for the trial and also undertake immunomonitoring in the treated patients.

After the completion of the study, immatics will have an exclusive first right to take a license to the data for further development of IMA950. No financial details were disclosed.

Paul Higham, CEO of immatics said: “Cancer Research UK is a world-renowned cancer research organisation and we are delighted that through this collaboration we will be able to efficiently move our third therapeutic cancer vaccine into the clinic, highlighting the wide applicability and productivity of our XPRESIDENT™ technology platform.”

Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office, said: “We’re very pleased to be taking on the next stage of this vaccine’s development. This form of glioma is very difficult to treat successfully and we hope this trial will help to establish if the immatics vaccine might offer another viable treatment option for people with this type of cancer.”
IMA950 is a therapeutic cancer vaccine generated through immatics’ proprietary XPRESIDENT™ technology. It consists of 11 tumour-associated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumour peptides is at the core of all immatics’ clinical programmes.
Advertisement